ischemic heart disease
Conditions
Brief summary
Incidence of the composite “all-cause mortality, non-fatal MI or stroke” at 12 months follow up., Safety Endpoint 1. Incidence of major bleeding at 12 months. This will be defined as bleeding academic research consortium scale (BARC) graded 3a to 5.
Detailed description
The incidence of the individual components of the primary composite., Death from cardiovascular causes, A composite of net adverse clinical benefit, including all-cause mortality, non-fatal MI or stroke and the incidence of BARC 3-5 bleeding at 12 months., Unplanned revascularization. This will include revascularization procedures that were not Preplanned during index hospitalization, BARC 2-5 bleeding at 12 months
Interventions
DRUGPRASUGREL
DRUGACETYLSALICYLIC ACID
DRUGTICAGRELOR
Sponsors
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of the composite “all-cause mortality, non-fatal MI or stroke” at 12 months follow up., Safety Endpoint 1. Incidence of major bleeding at 12 months. This will be defined as bleeding academic research consortium scale (BARC) graded 3a to 5. | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of the individual components of the primary composite., Death from cardiovascular causes, A composite of net adverse clinical benefit, including all-cause mortality, non-fatal MI or stroke and the incidence of BARC 3-5 bleeding at 12 months., Unplanned revascularization. This will include revascularization procedures that were not Preplanned during index hospitalization, BARC 2-5 bleeding at 12 months | — |
Outcome results
None listed